Navigation Links
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Date:6/3/2008

fective in specifically suppressing VEGF production."

The Molecular Vision study can be accessed at http://www.molvis.org/molvis/v14/a119/

"Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes," NS Dejneka, S Wan, OS Bond, DJ Kornbrust, SJ Reich, Molecular Vision, Volume 14, May 28, 2008

About OPKO Health, Inc.

Miami-based OPKO is a specialty healthcare company. Its lead investigational drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III trial after successfully completing Phase II trials for wet age-related macular degeneration and diabetic macular edema. OPKO is developing a preclinical pipeline of novel agents for ophthalmic diseases, and it markets innovative diagnostic imaging systems that complement the company's therapeutic products. For more information visit the company's website at http://www.opko.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential benefits and effectiveness of bevasiranib in suppressing the production of VEGF and reducing ocular neovascularization, our ability to establish OPKO's leadership position, our ability to aggressively engage in R&D activities and advance clinical testing of bevasiranib and our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Man
'/>"/>

SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
2. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
3. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
4. Newly Approved HIV Drug Shows Great Promise
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
11. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... officer of ViroPharma, will present at the Jefferies 2011 Global ... 2011.  The conference is being held in New York City. ... through www.viropharma.com and available for a period of ...
... be presented in a poster at the 2011 Annual Meeting ... in Chicago, Illinois June 3-7 by researchers from The University ... that a laboratory test developed by Biocept, Inc. for the ... Disseminated Tumor Cells (DTCs) can provide potentially valuable information to ...
Cached Medicine Technology:MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 2MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients 3
(Date:4/20/2014)... A single type of cell in the lining ... invasive bladder cancer, according to researchers at the Stanford ... mice, is the first to pinpoint the normal cell ... It,s also the first to show that most bladder ... one cell, and explains why many human bladder cancers ...
(Date:4/18/2014)... published online in The Gerontologist ... is associated with a decrease in anxiety about death ... control over their lives. In particular, listening to gospel ... death and an increase in sense of control. , ... and men, and individuals of both low- and high-socioeconomic ...
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Religious music brings benefit to seniors' mental health 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... efficacy of a malaria drug are being questioned by ... be withdrawn. Manufacturer GlaxoSmithKline markets the anti-malarial drug Malarone ... at preventing the aggressive falciparum strain of malaria, but ... the Consumers’ Association – says the evidence for this ...
... Depression is not the only factor contributing to a heightened ... suggest that suicide is a real risk when people suffer ... link - people with panic disorder often suffer from depression. ... ,However, a new study by doctors at Cleavland State ...
... often handled in a casual “insouciant” manner, with up ... receiving appropriate drugs, researchers say. Around 30,000 people are ... one-third can be expected to continue on long-term medication. ... College London have found that some epilepsy treatment regimes ...
... raise the risk of heart disease through causing inflammation of the ... scene for heart disease. A new study uncovers a link between ... Researchers at the University of Buffalo find that people with gum ... may be that oral bacteria enter the circulation via the gums, ...
... normal blood pressure is essential in the prevention of ... researchers. Dr Jan Staessen and colleagues from Leuven, in ... pharmacological properties of antihypertensive drugs or the reduction of ... hypertensive patients., // ,As part of a ...
... is little benefit in replacing older and cheaper antibiotics ... acute, uncomplicated sinusitis, according to US researchers. Researchers at ... determine whether the symptoms could be treated with older ... expensive (second-line) antibiotics. // ,Dr Jay Piccirillo ...
Cached Medicine News:
A quarter-vision dispensing case or table with a 6" high glass display area and halogen lights. Based on size of case, enjoy either 4, 5.5, 7 or 8 square feet respectively of elegant shelf space for ...
A compact showcase unit. Made with tempered glass, one, two or three adjustable shelves, a door with a safety lock. Equipped with fluorescent lighting and levelers. Display is available in various si...
Hoya Vision Care is focused on providing the best available most technically advanced and highest quality eye care products and services to the dispensing optometrist, ophthalmologist and optician....
... Essilor Laboratories of America ... trusted, spectacle lens lab network ... America. With in-house Crizal coating ... service and ensure premium quality ...
Medicine Products: